Last reviewed · How we verify

rituximab and everolimus — Competitive Intelligence Brief

rituximab and everolimus (rituximab and everolimus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody + mTOR inhibitor combination. Area: Immunology / Transplantation.

marketed Monoclonal antibody + mTOR inhibitor combination CD20 (rituximab); mTOR (everolimus) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

rituximab and everolimus (rituximab and everolimus) — National Taiwan University Hospital. This combination uses rituximab to deplete B cells via CD20 targeting and everolimus to inhibit mTOR signaling, together suppressing immune activation and proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
rituximab and everolimus TARGET rituximab and everolimus National Taiwan University Hospital marketed Monoclonal antibody + mTOR inhibitor combination CD20 (rituximab); mTOR (everolimus)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody + mTOR inhibitor combination class)

  1. National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rituximab and everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/rituximab-and-everolimus. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: